Profound Medical PROF 深 沪
已收盘 10-16 16:00:00 美东时间
6.01
-0.300
-4.75%
华盛通- 最 高6.44
- 今 开6.33
- 成交量 13.13万股
- 最 低 6.01
- 昨 收 6.31
- 总市值 2.20亿
- 52周最高 8.95
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 4.80
- 委 比 94.91%
- 总股本 3654.03万
- 历史最高 28.97
- 量 比 0.43
- 振 幅 6.81%
- 历史最低 3.10
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound Medical Corp. and Telix Pharmaceuticals have entered a co-education agreement to integrate Telix’s PSMA-PET imaging technologies with Profound’s MRI-guided TULSA-PRO platform for improved prostate cancer care. The collaboration aims to enhance physician education, optimize patient selection, and expand access to advanced treatment options. Profound plans to incorporate PSMA-PET data into future software updates, potentially improving tre...
10-09 11:45
Profound Medical Sees Q3 Sales $9.800M-$10.000M vs $6.934M Est
Profound Medical (NASDAQ:PROF) sees Q3 sales of $9.800 million-$10.000 million vs $6.934 million analyst estimate.
10-08 05:28
Profound Medical Forecasts Record Q3 Revenue, Far Exceeds Street Estimates
Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical ex...
10-08 05:02
Profound Medical expects Q3 revenue could top estimates by 47%
Profound Medical (PROF) announced on Wednesday that it expects Q3 revenue of $9.8M-$10.0M, up 85%-89% YoY and 292%-300% QoQ. The preliminary revenue range is about 45%-47% above the $6.78M Bloomberg c...
10-08 04:28
Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary unaudited revenues for the third quarter ended September 30, 2026. Preliminary...
10-08 04:16
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Profound Medical Corp. announced preliminary third-quarter 2026 revenues of $9.8 million to $10.0 million, surpassing Bloomberg analyst consensus by 45% to 47%. The company expects year-over-year growth of 85% to 89% and sequential growth of 292% to 300%. Gross margin is projected to exceed 70%, reflecting strong commercial momentum. CEO Arun Menawat highlighted the milestone as a significant step in expanding the company's commercial business. P...
10-07 20:15
Profound Medical Appoints Richard Fabian As President, Effective Immediately, Succeeding Mathieu Burtnyk
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately. Mr. Fabian ...
09-01 20:13
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
Profound Medical Corp. has appointed Richard Fabian as its new President, effective immediately, succeeding Mathieu Burtnyk, PhD, who has been named Chief Technology Officer. Fabian, with over 29 years of experience in healthcare, medical imaging, and medical devices, joins from FUJIFILM Sonosite, where he was CEO. He previously held various leadership roles at Philips Healthcare. Profound's CEO, Arun Menawat, expressed confidence in Fabian's abi...
09-01 12:00
Profound Medical names interim CFO
Profound Medical (PROF) promoted Matthew Sobczyk, its corporate controller since 2020, to interim chief financial officer, effective immediately. Sobczyk succeeds Rashed Dewan, who has stepped down as...
08-15 04:46
Profound Medical Announces Management Change
Profound Medical Corp. promotes Matthew Sobczyk to Interim Chief Financial Officer, succeeding Rashed Dewan. The company, a leader in interventional MRI (iMRI) procedures, develops TULSA-PRO for prostate ablation and Sonalleve for non-surgical treatments. These technologies are approved in major markets, offering precise, personalized care. Profound aims to advance MRI-guided therapies globally.
08-14 20:30
